Phyllis Whiteley, PhD., is a Venture Partner with Wildcat Venture Partners where she provides hands-on leadership in building, investing, and creating companies in the digital health space. Phyllis’ career is founded on her passion for personalized medicine, global healthcare, and transformative life science innovations. She has founded and built multiple companies in the United States and abroad.
Her executive expertise includes strategic planning, financing, partnerships, restructuring, building executive teams and M&A. Prior to joining Wildcat Venture Partners and Mohr Davidow Ventures, Phyllis was an Officer and Senior Vice President, Business Development, Licensing, and Alliance Management at Perlegen Sciences, Inc. Before joining Perlegen, she served as Vice President, Strategic Portfolio Management for Roche. Over her ten-year career with Roche she held various positions in Business Development based in Basel, Switzerland coupled with R&D leadership positions in the US. Phyllis also held a Senior Research Immunology role with Merck.
Phyllis currently serves on multiple boards including Balance Therapeutics, RainDance Technologies, Analyte Health (Chair), the Personalized Medicine Coalition (emeritus), UCSF Leadership Council for Global Health, and Springboard Enterprises, where she mentors women executives.
FACTS & STATS
Phyllis serves as a Global Social Benefits Mentor at Santa Clara University and is dedicated to helping social entrepreneurs address the problems of poverty, empower women, and build resilience to climate change.
Phyllis chairs the advisory board for the University of Texas Horizon Fund.
- Phyllis holds a BA in Chemistry and Ph.D. in Pharmacology from Washington University, St. Louis, Missouri.